A CLINICAL RESEARCH CAREER WORKING SPONSOR-SIDE, CRO-SIDE TO SITE-SIDE AT PARATUS CLINICAL
With
Megan Morrison,
Chief Executive Officer
Paratus Clinical
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Melbourne | December 2025
In July 2025, Paratus Clinical, a Australian provider of dedicated clinical trial services, announced the appointment of Megan Morrison as its new Chief Executive Officer, at the same time as a significant milestone as the company celebrating over a decade of impact in the clinical research space. Paratus now operates a network of five purpose-built, research-only clinics along Australia’s eastern seaboard.
Megan Morrison as the Chief Executive Officer of Paratus Clinical, brings more than 24 years of experience in the clinical research industry. She has held senior leadership roles across sponsor organisations, CROs and clinical sites, giving her a uniquely comprehensive perspective on the challenges and opportunities across the drug development ecosystem.
With a background in pharmacology and a Master of Business Administration, Megan combines scientific expertise with commercial and operational acumen. She is committed to advancing Australia’s role in global clinical research by expanding access to innovative studies, strengthening partnerships with sponsors, and ensuring that high-quality outcomes are delivered for both patients and partners.
In this interview with Australian Health Journal she talks about her career journey, current trends in the industry as well as recent projects. Megan also shares her career advice on being curious, in a frequently changing environment such as clinical research, for the benefit of sponsors getting new therapies to market.
Source: Adapted from Paratus Clinical media releases and website
You Might also like
-
Child Dental Benefits Schedule needing greater awareness
Since its launch in 2014, the Child Dental Benefits Schedule has seen a gradual increase in participation year on year. The impact of COVID-19 and related shutdowns saw participation fall sharply in 2020. Though it increased 2021, the national target of 41% participation was not reached in 2021-2022, with the total (35.4%) more than three percent below 2018 participation rates.
In an opinion segment, Australian Health Journal spoke with Abano Healthcare Group Clinical Director, Dr Fred Calavassy, with over 30 years of clinical experience, about his observations of the Child Dental Benefits Scheme ways to increasing participation rates.
-
Sharing the same goals in value-based procurement
Value-based procurement (VBP) is a journey, not a sprint. It’s about putting the patient at the centre of quality affordable healthcare through changes in procurement practices for medical technologies. Patient outcomes drive value and sustainability, not just price. The bigger picture indicates that VBP will create system cost saving through benefitting patients, rather than trying to attain the reverse – a win-win outcome.
-
Priming Australia for social prescribing
Social prescribing provides support in various areas of people’s lives, leading to increased confidence, improved navigation of systems, and enhanced friendships and trust in healthcare, while communities should be designed in an age-friendly way to prevent isolation.
In Part 1 of the Models of Care on Social Prescribing, Australian Health Journal spoke to 4 people advocating for social prescribing in Australia